Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25742
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHui, Rina-
dc.contributor.authorde Boer, Richard-
dc.contributor.authorLim, Elgene-
dc.contributor.authorYeo, Belinda-
dc.contributor.authorLynch, Jodi-
dc.date2021-01-
dc.date.accessioned2021-02-01T04:24:35Z-
dc.date.available2021-02-01T04:24:35Z-
dc.date.issued2021-01-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology 2021; 17 (Suppl 1): 3-14en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/25742-
dc.description.abstractPatients presenting with hormone receptor-positive (HR+ ), human epidermal growth factor receptor 2-negative (HER2- ) metastatic breast cancer (MBC) are usually treated with endocrine therapy (ET), except if there is a concern about endocrine resistance or a need to achieve rapid disease control due to visceral crisis. The combination of CDK4/6 inhibitor + ET has now replaced single-agent ET as the standard first-line treatment; and it can also be considered a standard option in the second-line setting. This review briefly summarizes recently reported efficacy findings from the key phase III clinical trials of CDK4/6 inhibitor + ET in patients with HR+ /HER2- MBC, including evidence that adding a CDK4/6 inhibitor to ET improves overall survival and does so without reducing patients' quality of life. There is still much to learn regarding the use of CDK4/6 inhibitors and how they may be optimally integrated into clinical practice. In particular, there is a need for specific biomarkers that help predict the likelihood of response or resistance to CDK4/6 inhibitor therapy; and for data to guide treatment decisions when a patient's disease progresses on a CDK4/6 inhibitor.en
dc.language.isoeng
dc.subjectCDK4/6 inhibitoren
dc.subjectHER2-negativeen
dc.subjectendocrine therapyen
dc.subjecthormone receptor-positiveen
dc.subjectmetastatic breast canceren
dc.subjectoverall survivalen
dc.subjectprogression-free survivalen
dc.subjectquality of lifeen
dc.titleCDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.en
dc.typeJournal Articleen
dc.identifier.journaltitleAsia-Pacific Journal of Clinical Oncologyen
dc.identifier.affiliationCancer Care Centre, St George Public Hospital, Kogarah, New South Wales, Australiaen
dc.identifier.affiliationAustin Healthen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationCrown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australiaen
dc.identifier.affiliationUniversity of Sydney, Sydney, New South Wales, Australiaen
dc.identifier.affiliationPeter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationEpworth-Freemasons Private Hospital, Melbourne, Victoria, Australiaen
dc.identifier.affiliationSt. Vincent's Clinical School, University of New South Wales, Sydney, New South Wales, Australiaen
dc.identifier.affiliationGarvan Institute of Medical Research, Sydney, New South Wales, Australiaen
dc.identifier.doi10.1111/ajco.13555en
dc.type.contentTexten
dc.identifier.pubmedid33506626
local.name.researcherYeo, Belinda
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextnone-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

40
checked on Feb 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.